Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
16 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Traumatic spinal cord injury less than 100 days.
Must be able to swallow tablets and sit upright.
Bilateral knee flexion contractures.
Pregnant, lactating or post-menopausal females.
Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.
Treatment in the last year with calcitonin, fluoride or anabolic steroid.
Keywords provided by Toronto Rehabilitation Institute:
Spinal Cord Injury
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Spinal Cord Injuries
Bone Diseases, Metabolic
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents